Mwanzo8QQ • FRA
add
AbCellera Biologics Inc
Bei iliyotangulia
€ 2.22
Bei za siku
€ 2.25 - € 2.25
Bei za mwaka
€ 1.70 - € 3.91
Thamani ya kampuni katika soko
777.75M USD
Wastani wa hisa zilizouzwa
275.00
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 5.05M | -44.98% |
Matumizi ya uendeshaji wa biashara | elfu -271.00 | -101.02% |
Mapato halisi | -34.21M | 27.44% |
Kiwango cha faida halisi | -677.43 | -31.88% |
Mapato kwa kila hisa | -0.12 | 25.00% |
EBITDA | -26.04M | 55.50% |
Asilimia ya kodi ya mapato | 26.95% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 625.61M | -17.75% |
Jumla ya mali | 1.36B | -8.57% |
Jumla ya dhima | 304.47M | -9.32% |
Jumla ya hisa | 1.06B | — |
hisa zilizosalia | 297.99M | — |
Uwiano wa bei na thamani | 0.62 | — |
Faida inayotokana na mali | -7.40% | — |
Faida inayotokana mtaji | -8.97% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Des 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -34.21M | 27.44% |
Pesa kutokana na shughuli | -8.00M | 59.21% |
Pesa kutokana na uwekezaji | 35.70M | 246.79% |
Pesa kutokana na ufadhili | 4.14M | 10.01% |
Mabadiliko halisi ya pesa taslimu | 29.68M | 175.92% |
Mtiririko huru wa pesa | -72.44M | -28,861.47% |
Kuhusu
AbCellera Biologics Inc. is a Vancouver, British Columbia-based contract research organization that is contracted by biotechnology and pharmaceutical companies for antibody services, and researches and develops human antibodies as a service for its clients. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2012
Makao Makuu
Tovuti
Wafanyakazi
596
